A Randomized, Controlled Clinical Trial of Exercise in Patients with Spinal Muscular Atrophy: Methods and Baseline Characteristics
Overview
Authors
Affiliations
Background: Spinal Muscular Atrophy (SMA) is a recessively-inherited neuromuscular disease characterized by weakness and muscle atrophy. Although anecdotal benefits from exercise have been noted, and despite promising pre-clinical and pilot reports, the effect of exercise has not been addressed in a controlled trial in SMA.
Objective: To assess the effects of exercise on measures of function, strength, and exercise capacity in ambulatory SMA patients.
Methods/design: An evaluator-blinded, randomized, controlled trial of aerobic and strengthening exercise in 14 ambulatory SMA patients aged 8-50 years. Patients will be randomized to either the exercise or control arm after the 1 month lead in period. During the first 6-months, the exercise group will receive the intervention while the other group serves as a control. After those 6 months, both groups will receive the intervention. The last 6-months of the study are designed to mimic real-world conditions where all participants are encouraged to continue on their own. Participants will be monitored throughout this 19 month study and will have in-person visits every three months. The primary outcome measure is the change in the total distance walked over 6-months on the six minute walk test (6MWT). Secondary outcome measures include maximal oxygen uptake (VO2 max), functional and strength assessments, pulmonary function, fatigue, and quality of life.
Discussion: The result of this prospective, single blinded, randomized and controlled clinical trial of exercise on an established functional outcome measure will have impact on clinical practice by providing important guidance to clinical management of SMA patients.
Prat-Ortega G, Ensel S, Donadio S, Borda L, Boos A, Yadav P Nat Med. 2025; .
PMID: 39910271 DOI: 10.1038/s41591-024-03484-8.
Ratia N, Palu E, Lantto H, Ylikallio E, Luukkonen R, Suomalainen A Front Neurol. 2023; 14:1277944.
PMID: 38020590 PMC: 10663357. DOI: 10.3389/fneur.2023.1277944.
How is Physical Activity Measured in Spinal Muscular Atrophy and Duchenne Muscular Dystrophy?.
Uher D, Yoon L, Garber C, Montes J J Neuromuscul Dis. 2023; 10(5):897-914.
PMID: 37424475 PMC: 10578218. DOI: 10.3233/JND-230033.
Spinal muscular atrophy - insights and challenges in the treatment era.
Mercuri E, Pera M, Scoto M, Finkel R, Muntoni F Nat Rev Neurol. 2020; 16(12):706-715.
PMID: 33057172 DOI: 10.1038/s41582-020-00413-4.
Kennedy R, Carroll K, McGinley J, Paterson K J Foot Ankle Res. 2020; 13(1):10.
PMID: 32122377 PMC: 7052968. DOI: 10.1186/s13047-020-0378-2.